Story preview
Topics in this story
Continue reading on the publisher site for the full article.
Read on publisher →TradingView
News Atlas is free and independent. If it’s useful to you, you can support it with a coffee. ☕ Buy me a coffee
Coverage
Tone
Outlets covering it
6
in the last 3 days
First reported
12 hr. ago
4 outlets since
Countries
5 other outlets reported this story in the last 3 days.
The financing will provide additional working capital for Sunshine Biopharma, but the inclusion of two warrants per unit creates potential future share dilution for existing shareholders. Key Investor TakeawaysSunshine Biopharma (NASDAQ:SBFM) has priced a $6 million public offering at $0.
FORT LAUDERDALE, FL / ACCESS Newswire / October 8, 2026 / Sunshine Biopharma Inc. NASDAQ:SBFM (the "Company"), a pharmaceutical company specializing in generic and specialty prescription medications, including drugs in the areas of oncology and antivirals, today announced the pricing of a public of…
On October 08, 2026, Sunshine Biopharma Inc (NASDAQ: SBFM) announced the pricing of a public offering expected to raise approximately $6 million in gross procee